Published in Clin Infect Dis on April 17, 2001
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis (2008) 2.25
Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis (2009) 2.13
The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med (2010) 2.01
Persistent pathogens linking socioeconomic position and cardiovascular disease in the US. Int J Epidemiol (2008) 1.80
Vaccination against Herpes Zoster and Postherpetic Neuralgia. J Infect Dis (2008) 1.70
Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis (2013) 1.54
Decreased TNF-alpha synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4+ T cells during aging. J Exp Med (2009) 1.29
A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clin Vaccine Immunol (2007) 1.25
Transcriptome analysis of age-, gender- and diet-associated changes in murine thymus. Cell Immunol (2007) 1.14
Impact of herpes zoster and post-herpetic neuralgia on patients' quality of life: a patient-reported outcomes survey. Z Gesundh Wiss (2010) 1.08
Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain. BMC Infect Dis (2011) 1.06
TLR-activated dendritic cells enhance the response of aged naive CD4 T cells via an IL-6-dependent mechanism. J Immunol (2010) 1.00
The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. Z Gesundh Wiss (2011) 0.98
CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection. PLoS Pathog (2011) 0.98
Concurrent multiple outbreaks of varicella, rubeola, german measles in unvaccinated children of co-educational mount carmel senior secondary school, thakurdwara palampur of northern himachal, India. J Family Med Prim Care (2015) 0.98
Tracing thymic output in older individuals. Clin Exp Immunol (2010) 0.97
IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies. Br J Cancer (2010) 0.97
Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older. Clin Vaccine Immunol (2009) 0.96
Epidemiology of herpes zoster infection among patients treated in primary care centres in the Valencian community (Spain). BMC Fam Pract (2010) 0.93
Annual incidence rates of herpes zoster among an immunocompetent population in the United States. BMC Infect Dis (2015) 0.92
An aged host promotes the evolution of avirulent coxsackievirus into a virulent strain. Proc Natl Acad Sci U S A (2006) 0.91
Postherpetic neuralgia in the elderly. Int J Clin Pract (2009) 0.90
Herpes zoster surveillance using electronic databases in the Valencian Community (Spain). BMC Infect Dis (2013) 0.89
Chickenpox, chickenpox vaccination, and shingles. Postgrad Med J (2006) 0.84
Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules. Hum Vaccin Immunother (2013) 0.82
Post-herpetic neuralgia. Int J Gen Med (2012) 0.82
Attenuation of the adaptive immune response in rhesus macaques infected with simian varicella virus lacking open reading frame 61. J Virol (2012) 0.82
Herpes zoster and the search for an effective vaccine. Clin Exp Immunol (2016) 0.81
Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Antimicrob Agents Chemother (2011) 0.80
The burden of disease of Herpes Zoster in Tuscany. Hum Vaccin Immunother (2014) 0.80
Reducing the burden of Herpes Zoster in Italy. Hum Vaccin Immunother (2014) 0.79
Investigation of the cutaneous response to recall antigen in humans in vivo. Clin Exp Immunol (2013) 0.78
Neuronal changes induced by Varicella Zoster Virus in a rat model of postherpetic neuralgia. Virology (2015) 0.78
Acupuncture for the treatment of severe acute pain in herpes zoster: results of a nested, open-label, randomized trial in the VZV Pain Study. BMC Complement Altern Med (2011) 0.77
Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years. Hum Vaccin (2011) 0.77
End-stage renal disease (ESRD) contributes to the increasing prevalence of herpes zoster. NDT Plus (2009) 0.77
VZV meningitis following varicella vaccine. J Clin Virol (2010) 0.76
Herpes zoster-associated mortality in Europe: a systematic review. BMC Public Health (2015) 0.76
Burden of herpes zoster-associated chronic pain in Italian patients aged 50 years and over (2009-2010): a GP-based prospective cohort study. BMC Infect Dis (2014) 0.76
Dementia following herpes zoster encephalitis. Clin Neuropsychol (2010) 0.76
Evaluation of the acceptability of a vaccine against herpes zoster in the over 50 years old: an Italian observational study. BMJ Open (2016) 0.75
Thermal patterns in zoster. J Med Life (2015) 0.75
Incidence of herpes zoster and post-herpetic neuralgia in Italy: Results from a three-years population-based study. Hum Vaccin Immunother (2016) 0.75
Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia. BMJ Open (2017) 0.75
The Uncommon Localization of Herpes Zoster. Med Arch (2016) 0.75